Mican, in reading the article, I found this curious:
"Roche has earned a reputation as a disciplined acquirer, prepared to walk away from potential deals rather than overpay."
"Chief Executive Severin Schwan abandoned a $6.8 billion deal to buy U.S gene sequencing company Illumina in 2012"
Current market cap of ILMN is over $23 billion. I have thought of a reputation to label Roche with, but it may get my post deleted. I will abandon my plans to acquire any shares of Roche.
Rum